EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Lung Carcinoids—Time to Change Practices

Ana Rodrigues iD, Nuno Coimbra iD, Inês Lucena Sampaio, Isabel Azevedo, Marta Soares, Carmen Jerónimo iD, Rui Henrique iD

Current Oncology · 2026

DOI: 10.3390/curroncol33010050 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Current Oncology, 2026. Verfasst von Ana Rodrigues und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoid Tumor. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung carcinoids—typical and atypical—are rare neuroendocrine tumors (NETs) representing 1–2% of lung cancers. Despite clinicopathological differences, their clinical management often mirrors lung cancer protocols rather than NET-specific recommendations.

Objectives

Portray a 12-year real-world experience with lung carcinoids at a Comprehensive Cancer Center, identifying gaps in diagnostic work-up, treatment decision-making, and follow-up.

Methods

Retrospective observational cohort study of adult patients with histologically confirmed lung carcinoids diagnosed at IPO Porto between January 2013 and December 2024. Demographic, clinical, imaging, and treatment data were collected from electronic patient records. Analyses were descriptive.

Results

Among 179 identified cases, 129 met eligibility criteria. Median age was 62 years (range 18–84); 53.6% were women and 53.5% were non-smokers; 84.5% had ECOG-PS 0–1. The most frequent presentation was respiratory symptoms (34.1%), followed by incidental findings (43.4%, of which ~20% were during staging or surveillance of other cancers). Typical carcinoids accounted for 49.6% and atypical for 43.4%. FDG-PET/CT was requested in 70.9% of cases, including many with typical carcinoid, and SSTR-PET/CT in 64.6% (dual PET in 38.8%). Most patients (65.1%) presented with stage I disease; 17.1% were stage IV. Mean time-to-first treatment was 83 days (range 1–259). Surgery was the first treatment option for 78.3% of patients.

Conclusions

This real-world series highlights heterogeneity in diagnostic pathways, excessive FDG-PET use in typical carcinoids, and non-standardized follow-up. Dedicated multidisciplinary lung-NET boards and national reference centers are needed to homogenize and streamline patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoid TumorHumansFemaleMiddle AgedMaleAgedAdultRetrospective StudiesAged, 80 and overAdolescentYoung Adult

Stichwörter der Autor:innen

lung carcinoidsneuroendocrine tumorsreal-world dataretrospective study

Autor:innen und Institutionen

  • Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal.
  • Thoracic and Mediastinal Tumors Clinic, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-162 Porto, Portugal.
  • Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-162 Porto, Portugal.
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) IPOP/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruc…
  • Department of Nuclear Medicine, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-162 Porto, Portugal.
  • Department of Pathology and Molecular Immunology, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal.

ORCID-Profile: Ana Rodrigues, Nuno Coimbra, Carmen Jerónimo, Rui Henrique

Zitieren

APA

Rodrigues, A., Coimbra, N., Sampaio, I. L., Azevedo, I., Soares, M., Jerónimo, C., & Henrique, R. (2026). Lung Carcinoids—Time to Change Practices. Current Oncology. https://doi.org/10.3390/curroncol33010050

Vancouver

Rodrigues A, Coimbra N, Sampaio IL, Azevedo I, Soares M, Jerónimo C, et al. Lung Carcinoids—Time to Change Practices. Current Oncology. 2026. doi:10.3390/curroncol33010050

BibTeX
@article{Rodrigues2026,
  author = {Rodrigues, Ana and Coimbra, Nuno and Sampaio, Inês Lucena and Azevedo, Isabel and Soares, Marta and Jerónimo, Carmen and Henrique, Rui},
  title = {Lung Carcinoids—Time to Change Practices},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33010050}
}
Kostenlos starten →